Yuki Endo

8PUBLICATIONS
16CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 15, 2026
Meaningful Radiographic and Metabolic Response to Enzalutamide Plus Radium-223 Therapy in Metastatic Castration-Resistant Prostate Cancer With PSA-Discordant Progression: A Case Report.

|Jun 03, 2026
Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.

|Mar 27, 2026
Avelumab maintenance therapy for advanced urothelial carcinoma: subgroup analyses by characteristics of first-line platinum-based chemotherapy from a real-world chart review study in Japan (JAVEMACS).

Yuki Endo, Hiroshi Kitamura, Suguru Shirotake

|Dec 11, 2025
A Composite Risk Score Based on VI-RADS, Tumor Contact Length, and CYFRA 21-1 for Prognostic Stratification in Bladder Cancer.

Shunsuke Ikuma, Jun Akatsuka, Godai Kaneko

|Aug 27, 2025
Impact of Surgical Margin Control in Index Tumors on Prognosis After Radical Prostatectomy: A Focus on Zonal Origin.

Jun Akatsuka, Yoshihiko Ogata, Kotaro Obayashi

|Aug 27, 2025
Prognostic Utility of Combining VI-RADS Scores and CYFRA 21-1 Levels in Bladder Cancer: A Retrospective Single-Center Study.

Shunsuke Ikuma, Jun Akatsuka, Godai Kaneko

Pageof 2

Frequent Collaborators

6 joint publications

Go Kimura

6 joint publications

Yukihiro Kondo

4 joint publications

Hayato Takeda

3 joint publications

Shunsuke Ikuma